Predatory efficiency of the sewage drain inhabiting larvae of Toxorhynchites splendens Wiedemann on Culex quinquefasciatus Say and Armigeres subalbatus (Coquillett) larvae

The rate of predation by stage IV instar Toxorhynchites splendens larvae on the equivalent instar stage larvae of Culex quinquefasciatus and Armigeres subalbatus, co-occurring in sewage drains, were noted for a period of three consecutive days in the laboratory using different prey densities and combinations. The rate of predation varied by age of the predator, density of prey, and prey type. The number of Ar. subalbatus larvae consumed by a single Tx. splendens larva ranged between 0.50 +/- 0.71 and 16.40 +/- 2.01; while for Cx. quinquefasciatus larvae, the number consumed ranged from 0.20 +/- 0.42 to 20.40 +/- 1.43 per day. The pupation rates of the prey species varied in respect to control, with a minimum of 0.20 +/- 0.42 pupa/day to a maximum of 12.20 +/- 2.30 pupa/day in the presence of Tx. splendens. The values for the controls were 1.00 +/- 0.87 and 14.44 +/- 2.83 pupa/day, respectively. Irrespective of prey densities and combinations, a single Tx. splendens fourth instar larvae was found to consume on average 10.07 larvae on the first day 16.57 larvae on the second day and 4.38 larvae on the third day, killing a total of 17.70 to 45.10 larvae, in three days. In the presence of Tx. splendens, the cumulative pupation, irrespective of prey, remained between 12.20 and 45.10, and differed significantly from control where the values were between 13.90 and 54.70. The results indicate that Tx. splendens can significantly reduce immature numbers and lower the rate of pupation of Cx. quinquefasciatus and Ar. subalbatus. Tx. splendens may be a potential biological resource in the control of mosquitoes inhabiting sewage drains.     

New method for calcium on the ADVIA analyzer is free from interference of gadolinium‐type contrast agents

Recently, Siemens Diagnostics released a new calcium assay (CA_2) based on complex formation of calcium with Arsenazo III dye for use on the three automated, random access ADVIA Chemistry analyzers (1650, 2400, and 1200). We evaluated this method for analytical performance as well as potential interference from gadolinium‐containing magnetic contrast agents. With Siemens Chemistry serum and urine controls, 2‐levels each, the imprecision for the new method was (n=40 each): within‐run and total CV of <2.2 and <3.8%, respectively, over all three platforms. The analytical range/linearity of the method (all three systems) was 1–16 mg/dl (serum or plasma) and 1–32 mg/dl (urine). The new method on all three platforms correlated well with a reference (Inductively Coupled Plasma Atomic Emission Spectroscopy) method (n=61, range 4.03–10.30 mg/dl). The ADVIA 1650 CA_2 method also correlated well with the Roche Modular system^® Calcium method. The new method showed <10% interference with unconjugated or conjugated bilirubin (50 mg/dl), hemoglobin (1,000 mg/dl), lipids (1,000 mg/dl), and two magnetic resonance contrast agents containing Gadolinium (OptiMARK^® 1 mmol/l and Omniscan 1.5 mmol/l). On the contrary, the Roche Calcium method showed significant negative interference with gadolinium‐containing contrast agents. We conclude that the ADVIA Ca_2 method can measure serum, plasma, or urine calcium concentrations accurately and is also free from interferences of gadolinium‐containing agents. J. Clin. Lab. Anal. 23:399–403, 2009. © 2009 Wiley‐Liss, Inc.     

New enzyme-linked chemiluminescent immunosorbent digoxin assay is free from interference of Chinese medicine DanShen

DanShen is a traditional Chinese medicine indicated for cardiovascular diseases. The potential interference of DanShen with serum digoxin measurement was investigated using a new enzyme-linked chemiluminescent immunosorbent (ECLIA) digoxin assay. Aliquots of drug-free serum were supplemented with ethyl acetate extract of DanShen (4 different brands studied), and apparent digoxin concentrations were measured by the ECLIA as well as fluorescence polarization immunoassay (FPIA) and a turbidimetric assay for comparison. Mice were also fed 4 DanShen preparations and apparent digoxin concentrations were subsequently measured. In another experiment, serum pools containing digoxin were further supplemented with DanShen extracts and digoxin concentrations were measured again by all 3 assays. No apparent digoxin concentration was observed when aliquots of drug-free serum pools were supplemented with DanShen and digoxin concentrations were measured by the ECLIA or the turbidimetric assay. In contrast, significant apparent digoxin concentrations were observed using FPIA, and the highest apparent digoxin concentration was observed with brand 4 of DanShen extract. Similarly, when mice were fed with this herb, significant apparent digoxin concentrations were also observed using FPIA, but neither ECLIA nor turbidimetric assay showed any apparent digoxin concentration. When aliquots of digoxin pool were further supplemented with various DanShen extract, the apparent digoxin concentrations were significantly increased when FPIA was used. In contrast, digoxin concentrations in the presence of DanShen extract compared well with the digoxin concentration of the original pool when ECLIA or turbidimetric assay was used. We conclude that DanShen does not interfere with serum digoxin measurement using a more recently released ECLIA digoxin assay.     

Drug trafficking routes and hepatitis B in injection drug users, Manipur, India

Prevalence of hepatitis B genotype C in injection drug users in the northeastern Indian state of Manipur, neighboring the "Golden Triangle," correlates well with overland drug-trafficking routes, the injection drug use epidemic, and the spread of HIV. Further spread to other regions of India through mobile populations is possible.     

Method of Delivery and Neonatal Mortality among Very Low Birth Weight Infants in the United States

OBJECTIVE: To examine the association between method of delivery (primary cesarean section vs. vaginal) and neonatal mortality risk (as well as causes of death) among very low-birth weight first-born infants in the United States. More specifically, to examine this association separately for breech/malpresenting and vertex-presenting infants, while adjusting for selected maternal characteristics, and pregnancy, labor and delivery complications. METHODS: The study population was derived from the 1995-1998 birth cohort linked birth/infant death data sets. Binary and multinomial logit regression analyses were performed to assess the relationship in four very low-birth weight categories. RESULTS: Among breech/malpresenting neonates, compared to those delivered vaginally, infants delivered by a primary cesarean section had significantly lower adjusted relative risks of death for all very low-birth weight categories and the decrease in relative risk tended to be larger with each increasing birth weight category. However, for vertex-presenting neonates, results are mixed, suggesting decreased relative mortality risks associated with primary cesarean section, which were significant for 500-749 g, not significant for 750-999 g, and barely significant for 1,000-1,249 g. In contrast, for vertex-presenting neonates weighing 1,250-1,499 g, there was a significantly increased adjusted relative risk associated with primary cesarean section. Differences in cause-specific neonatal mortality by method of delivery and presentation status were also discussed. CONCLUSIONS: Primary cesarean section appears to be associated with decreased neonatal mortality risks in each very low-birth weight category for breech/malpresenting infants, but results are mixed for vertex-presenting infants. Causal inferences should be avoided because this was an observational study by design.     

Interference of endogenous digoxin-like immunoreactive factors in serum digoxin measurement is minimized in a new turbidimetric digoxin immunoassay on ADVIA 1650 analyzer

Endogenous digoxin-like immunoreactive factors (DLIF) cross-react with antidigoxin antibody and falsely elevate or lower measured serum digoxin concentrations, depending on the assay design. Recently, Bayer Diagnostics released a turbidimetric assay for digoxin on the ADVIA 1650 analyzer. We studied potential interference of DLIF with this new digoxin assay. We analyzed 40 serum specimens from patients who have pathologic conditions that may increase serum DLIF concentrations. These patients were never exposed to digoxin or other agents that may lead to a measurable digoxin concentration. We also analyzed five specimens from autopsy and five specimens from neonates. Apparent digoxin concentrations were measured using the new turbidimetric digoxin assay, the fluorescence polarization immunoassay (FPIA, Abbott Laboratories, Abbott Park, IL), and also the chemiluminescent immunoassay (CLIA, Bayer Diagnostics). We observed measurable apparent digoxin levels with the FPIA in 5 uremic patients (range 0.24-0.86 ng/mL), 6 patients with liver disease (range 0.21-0.72 ng/mL), in 3 patients in the third trimester of pregnancy (0.21-26 ng/mL), and in 3 neonates (range 0.21-0.46 ng/mL). Four out of 5 autopsy specimens showed measurable apparent digoxin concentrations (0.23-0.81 ng/mL). In contrast, only 1 specimen (a uremic patient) showed an apparent digoxin concentration of 0.26 ng/mL with the turbidimetric digoxin immunoassay (FPIA value 0.86 ng/mL, CLIA value 0.32 ng/mL). Because DLIF is absent in the protein-free ultrafiltrate, we also measured free digoxin concentrations in DLIF-positive patients to ensure that the apparent digoxin concentrations were caused by DLIF. We observed no apparent digoxin concentrations in the protein-free ultrafiltrate in any DLIF-positive specimens. When serum specimens containing elevated concentrations of DLIF but no digoxin were supplemented with a known concentration of digoxin, we observed falsely elevated digoxin concentrations by the FPIA, as expected. In contrast, we observed a good agreement between the target and observed concentrations when the new turbidimetric assay was used. We conclude that DLIF has minimal effect on serum digoxin measurements by the new turbidimetric assay.     

Rapid detection of oleander poisoning using digoxin immunoassays: comparison of five assays

Oleander is an ornamental shrub that grows in the United States, Australia, India, Sri Lanka, China, and other parts of the world. All parts of the plant are poisonous because the presence of cardiac glycoside oleandrin. Despite its toxicity, oleander extract is used in folk medicines. Because of its structural similarity, oleandrin cross-reacts with the fluorescence polarization immunoassay (FPIA) for digoxin. We studied the potential of detecting oleandrin in serum using 5 common digoxin immunoassays (FPIA, MEIA, both from Abbott; Beckman digoxin assay on Synchron LX, Chemiluminescent assay, CLIA from Bayer Diagnostics) and a recently FDA-approved turbidimetric assay on the ADVIA 1650 analyzer (Bayer). Aliquots of drug-free and digoxin-like immunoreactive substances (DLIS)-free serum pools were supplemented with ethanol extract of oleander leaves or oleandrin (Sigma Chemicals) in amounts expected in vivo after severe overdose. We observed significant apparent digoxin concentration with FPIA, Beckman, and the new turbidimetric assay (1 mL drug-free serum supplemented with 5.0 microL of oleander extract: apparent digoxin 2.36 ng/mL by the FPIA, 0.32 ng/mL by the MEIA, 0.93 ng/mL by the Beckman, 0.82 ng/mL by the new turbidimetric assay). The CLIA showed no cross-reactivity. Similar observations were made when serum pools were supplemented with oleandrin. Because cross reactivity should be tested in the presence of the primary analyte, we supplemented serum pools prepared from patients receiving digoxin with oleander extract or oleandrin. The measured digoxin concentrations were falsely elevated with the FPIA, Beckman, and turbidimetric assays, the highest false elevation being observed with the FPIA. Surprisingly, apparent digoxin concentrations were falsely lowered when MEIA was used. Digibind neutralizes free apparent digoxin concentration in vitro in serum pools supplemented with oleander extract, and this effect can be measured by the FPIA. We conclude that FPIA is most sensitive to detect the presence of oleander in serum. In contrast, the CLIA (no cross-reactivity) should be used for monitoring digoxin in a patient receiving digoxin and self-medicated with a herbal remedy containing oleander.     

Racial differences in leading causes of infant death in the United States

We used linked birth/infant death records of over 23 million singletons belonging to six birth cohorts (1989-91 and 1995-97) and examined changes in race differentials in the overall and cause-specific infant mortality risks across time in the United States. Results show that infant mortality declined for all races during the time period, with disproportionately greater declines among non-Hispanic American Indians (AIs). Among the leading causes of infant death, declines in mortality from sudden infant death syndrome (SIDS), respiratory distress syndrome (RDS) and congenital anomalies contributed the most to the overall decline in infant mortality in the 1995-97 cohorts, compared with the 1989-91 cohorts. Disproportionately greater reductions in mortality resulting from SIDS and congenital anomalies led to more rapid mortality declines among non-Hispanic AIs than for other races. There are disturbing findings that infants of almost every race experienced increases in mortality from newborn affected by maternal complications of pregnancy (maternal complications) and that none of the race groups experienced a significant decline in mortality from disorders resulting from short gestation/low birthweight.     

Pharmacological characterization of human S1P4 using a novel radioligand, [4,5-3H]-dihydrosphingosine-1-phosphate

Sphingosine-1-phosphate (S1P) is a bioactive lipid that affects a variety of cellular processes through both its actions as a second messenger and via activation of a family of G protein-coupled receptors (S1P(1-5)). The study of S1P receptor pharmacology, particularly S1P(4), has been hindered by the lack of high-affinity radioligands with good specific activity. The studies presented herein characterize [(3)H]DH-S1P as a stable, high-affinity radioligand for S1P(4) pharmacology. Using a transfected Ba/F3 cell line selected for high hS1P(4) surface expression, we compared the consequences of different cellular backgrounds and commercial sources of sphingophospholipids on S1P(4) characterization. The development and subsequent use of the assay described has enabled us to extensively and definitively characterize the pharmacology of the human S1P(4) receptor.